[Abstract] Viral pseudotyped particles (pp) are enveloped virus particles, typically derived from retroviruses or rhabdoviruses, that harbor heterologous envelope glycoproteins on their surface and a genome lacking essential genes. These synthetic viral particles are safer surrogates of native viruses and acquire the tropism and host entry pathway characteristics governed by the heterologous envelope glycoprotein used. They have proven to be very useful tools used in research with many applications, such as enabling the study of entry pathways of enveloped viruses and to generate effective genedelivery vectors. The basis for their generation lies in the capacity of some viruses, such as murine leukemia virus (MLV), to incorporate envelope glycoproteins of other viruses into a pseudotyped virus particle. These can be engineered to contain reporter genes such as luciferase, enabling quantification of virus entry events upon pseudotyped particle infection with susceptible cells. Here, we detail a protocol enabling generation of MLV-based pseudotyped particles, using the Middle East respiratory syndrome coronavirus (MERS-CoV) spike (S) as an example of a heterologous envelope glycoprotein to be incorporated. We also describe how these particles are used to infect susceptible cells and to perform a quantitative infectivity readout by a luciferase assay.
successfully used this method to pseudotype viral envelope glycoproteins from all three classes of viral fusion proteins: influenza hemagglutinin (HA, class I), coronavirus spike (S, class I), Ebola glycoprotein (GP, class I), Semliki forest virus (SFV) E1 (class II), and vesicular stomatitis virus (VSV) G glycoprotein (class III). The technique described here is based on work performed by Bartosch and colleagues (Bartosch et al., 2003) , and employs the so-called 'three-plasmid' co-transfection strategy in which producer HEK-293T/17 cells are co-transfected with the following plasmids: a plasmid allowing expression of MLV retroviral core genes gag and pol but lacking the MLV envelope glycoproteinencoding env gene, a transfer vector containing a luciferase reporter gene flanked by retroviral regulatory LTR regions and a packaging signal, along with a plasmid allowing expression of the desired envelope glycoprotein. The co-expression of these three plasmids allows synthesis of LTR-flanked reporter gene-containing RNA, MLV-derived proteins and heterologous envelope glycoprotein. During pseudotyped particle formation, which occurs at the plasma membrane, the RNAs containing the LTRflanked luciferase gene get incorporated into nascent particles formed by assembly and budding of MLV capsid proteins that also recruit heterologous viral envelope glycoproteins. Upon infection in susceptible cells, the pseudotyped virus entry pathway is solely governed by the heterologous virus envelope glycoprotein used. As such, pseudovirions are excellent surrogates to study the entry pathway of enveloped viruses. Once virus entry has occurred, the pseudotyped virus RNAs are released in the cell and the retroviral reverse transcriptase and integrase then reverse transcribe the molecules into double stranded DNA and integrate them into the genome of target cells. Because the sequence that gets integrated only contains the gene encoding the luciferase reporter but none of the MLV genes, the pseudotyped particles are inherently safer as they only allow for one round of infection. After infection, a simple luciferase assay allows quantification of infectivity of the pseudotyped particle studied.
The following protocol can form the basis of useful experiments for the study of the heterologous envelope glycoprotein function during virus entry, for example by performing the infection assay using different infection conditions such as receptor/co-receptor expression in target cells, virus binding time and temperature, pH, endocytosis inhibitors, protease inhibitors, neutralizing antibodies, etc. b. pTG-Luc (ampicillin resistance) (Bartosch et al., 2003) c. pCAGGS-MERS-S (ampicillin resistance) (Millet and Whittaker, 2014) 1. Pre-warm cell-culture reagents required in 37 °C water bath: DMEM-C, DPBS, trypsin.
Materials and Reagents

Note: This is a particularly important step since HEK-293T/17 cells are poorly adherent -see
Note 2 for details.
2. Turn on biosafety cabinet for at least 15 min before starting procedures.
3. Disinfect all internal surfaces of biosafety cabinet (except top grills) with 70% ethanol-soaked paper towels.
B. Cell seeding (performed in biosafety cabinet)
1. Place an 80-90% confluent T75 flask (check by visual inspection using an inverted light microscope) containing HEK-293T/17 cells in sterilized biosafety cabinet.
2. Wash cells twice with 10 ml of pre-warmed DPBS being careful not to dispense liquid directly on cells.
3. Trypsinize cells with 1 ml of pre-warmed trypsin solution.
4. Rock plate gently with hands so the trypsin solution covers the entire surface of cell monolayer.
5. Incubate cells at 37 °C 5% CO2 incubator for 3-5 min avoiding longer incubation times.
Note: It is crucial to avoid long trypsin incubation times because this typically leads to cells
clumping -see Note 3.
6. Gently tap sides of flask to detach cells.
7. Place trypsinized flask back into biosafety cabinet.
8. Add 4 ml of warmed DMEM-C to neutralize trypsin activity.
9. Resuspend cells by performing repetitive up-down pipetting using a 5 ml serological pipette.
10. Add 5 ml of DMEM-C to cells and resuspend cells again.
11. Transfer 10 ml of cell suspension to a 50 ml Falcon tube.
12. Vortex cells gently for 30 sec.
www.bio-protocol.org/e2035 13. Transfer 10 µl of cell suspension to a cell counting chamber using a P20 pipettor and appropriate tip.
14. Count cells using the cell counting chamber under an inverted light microscope.
15. Calculate cell density using the calculator.
16. Add DMEM-C to obtain a final cell density of 5 x 10 5 cells/ml. Scale bar represents 100 µm.
2. Warm Opti-MEM in 37 °C incubator.
3. Calculate volumes of plasmid DNA and Opti-MEM required for mix A (the quantities given for 1 well of a 6-well plate can be scaled-up or down depending on needs).
For 1 well of a 6-well plate (1 µg total DNA transfected):
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10. Use a 1:1 ratio (i.e., 50 µl each for one well to transfect) of mix A and B and mix solutions by performing multiple up-down pipetting.
11. Incubate at room temperature for 20 min.
12. Place plate of cells to be transfected in incubator and label wells to be transfected with name of viral enveloped used.
13. Aspirate supernatants gently and replace with 1 ml of warmed Opti-MEM.
14. Add 100 µl of transfection mix to each well in a drop-wise manner.
15. Gently rock plates front and back and side to side.
16. Incubate in 37 °C 5% CO2 incubator for 4-6 h.
17. Pre-warm transfection DMEM (DMEM-T, no antibiotics) in 37 °C water bath.
Note: DMEM-T is used here instead of DMEM-C because the transfection reagent increases
cell membrane permeability, which leads to enhanced susceptibility to the cytotoxic effects of antibiotics in the cell culture medium -see Note 4.
18. Add gently 1 ml of DMEM-T to each well.
19. Incubate in 37 °C 5% CO2 incubator for 48 h.
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3. Spin tubes in centrifuge at 290 x g for 7 min.
4. Pass pseudotyped virus solution through a 0.45 µm filter using appropriate syringe.
5. Aliquot solution in labeled cryovials (e.g., 1 ml aliquots).
6. Store tubes at -80 °C -see Note 7 for more details on storage.
7. Decontaminate with 10% bleach solution all culture vessels, serological pipettes, syringes that have come into contact with pseudotyped virus solutions, with a minimum contact time of 15 min.
Note: This protocol describes how to produce and use pseudotyped particles for infectivity assays. To estimate quantities of particles produced as well as incorporation of specific viral envelope glycoproteins into particles, additional experiments are required such as Western blot analyses or ELISA assays -see Note 8 for details.
E. Cell seeding for infection (performed in biosafety cabinet)
1. Place an 80-90% confluent T75 flask containing Huh-7 cells in biosafety cabinet.
2. Wash cells twice with 10 ml of warmed DPBS being careful not to dispense liquid directly on cells.
3. Trypsinize cells with 1 ml of warmed trypsin solution.
Incubate cells at 37 °C 5% CO2 incubator for 3-5 min avoiding longer incubation times.
Note: It is important to avoid long trypsin incubation times because this typically leads to the clumping of cells as well as cell counting and density problems -see Note 3.
7. Place trypsinized flask back in biosafety cabinet.
9. Resuspend cells by performing repetitive up-down pipetting using a 5 ml serological pipettor.
Add 2-3 ml of DMEM-C to cells and resuspend cells again (adjust depending on cell confluency).
11. Transfer cell suspension to a 50 ml Falcon tube.
12. Vortex cells gently for around 30 sec.
13. Transfer 10 µl of cell suspension to a cell counting chamber using a P20 pipettor and appropriate tip.
14. Count cells using the cell counting chamber under a light microscope.
15. Calculate cell density using a pocket calculator.
16. Add DMEM-C to obtain a final cell density of 5 x 10 5 cells/ml.
www.bio-protocol.org/e2035 Figure 2 ). 8. Place the plate on rocker located in 37 °C 5% CO2 cell culture incubator.
Note: Alternatively, cells can be placed in incubator without rocker.
9. Incubate cells for 1-2 h.
10. Pre-warm DMEM-C in 37 °C water bath.
11. Add 300 µl DMEM-C using a repeater dispenser and appropriate tip.
12. Incubate at 37 °C 5% CO2 cell culture incubator for 72 h.
Note: This infection time can be optimized if required, see Note 9.
13. Decontaminate with 10% bleach solution all culture vessels and pipette tips, that have come into contact with pseudotyped virus solutions, with a minimum contact time of 15 min.
Day 8
G. Luciferase assay (performed in biosafety cabinet until step G5)
1. Bring luciferase assay lysis buffer (stored at -20 °C) and luciferin substrate (stored at -80 °C) at room temperature.
Place plate containing infected cells in biosafety cabinet and incubate until temperature has
equilibrated to room temperature.
3. Dilute to 1x luciferase assay lysis buffer with sterile water.
4. Aspirate gently the supernatants of cells.
5. Add 100 µl of 1x luciferase assay lysis buffer to each well using the repeater dispenser.
6. Incubate on rocker at room temperature for 15 min (after incubation, plate can be opened outside of biosafety cabinet). 3. Average measurements of independent experiments for statistical significance analysis.
4. Plot data using graph plotting software such as Prism 7 (an example of plotted data is shown in Figure 3 ). 
Transfection recommendations
The ratio of amounts of plasmid DNA used (300 ng pCMV-MLVgag-pol:400 ng pTG-Luc:300 ng envelope-encoding or empty vector) can also be optimized if required (e.g., to increase pseudovirion infectivity), but we recommend to keep the amounts of pCMV-MLVgag-pol and pTG-Luc vectors constant and vary the amount of envelope-encoding vector. Furthermore, in this protocol we have used a 1 µg DNA:3 µl Lipofectamine 2000 ratio for the transfections, which has worked very well for our pseudotyped particle productions. However, depending on the expression plasmids and cell lines used, it may be useful to carry out testing and optimization of this ratio. Also, as the transfection procedure increases cell membrane permeability, it is important to avoid antibiotic treatment of cells during that time. Doing so ensures that the cytotoxicity associated with the transfection remains low.
Pseudotyped particle production and infection scaling
The following protocol is performed using 6-well plates for the transfection of HEK-293T/17 producer cells. From one well of a 6-well plate, approximately 2 ml of pseudotyped particle supernatant can be harvested. If more pseudotyped particle solution is required, the same transfection can be performed in multiple wells with the supernatants pooled at the harvesting stage. The protocol can also be scaled up or down depending on needs, by using other culture vessels (such as 10 cm dish or flasks) and by adjusting transfection conditions accordingly. The protocol also details how infection of target cells with pseudotyped particles is performed using 24-well plates. This can also be scaled to the needs of an experiment, for example for highthroughput experiments, the assay can be optimized for infections carried out in 96-well plates by adjusting volumes and using a plate-compatible luminometer.
Pseudotyped particle production controls
During production of pseudotyped particles, it is important to include particle production controls, an important step that is detailed in this protocol. Typically, 'bald' or '∆env' particles (∆envpp)
are produced by replacing the plasmid encoding the heterologous viral enveloped glycoprotein with an empty vector control. These particles bud out of producer cells, but are devoid of viral envelope glycoproteins. Also, a positive control is also useful to gauge how well the procedure was performed, and typically VSV-G-pseudotyped particles (VSV-Gpp) are used for this. These particles usually reach very high infectivity in many cell types and are thus ideal positive controls. capsid protein released from producer cells (p30 protein for MLV) or with a direct total particle count and analysis using devices such as Nanosight (Millet et al., in press ). The Western blot technique also allows to probe for the heterologous envelope protein, which is very useful for assessing efficiency of its incorporation in pseudotyped particles.
Incubation times
The incubation times (48 h during production and 72 h for infection assay) have been optimized for MERS-CoV S-pseudotyped particles. These incubation times can be used as guidelines for generating other types of pseudovirions, however, we recommend testing different incubation times to optimize virus production and infectivity.
Pseudotyping more than one envelope glycoprotein
This protocol describes the procedures to generate pseudotyped particles that harbor only one kind of envelope glycoprotein, for example the MERS-CoV S protein in the case of MERS-Spp.
However, using the co-transfection strategy, it is possible to incorporate more than a single envelope protein. For example, we have successfully generated influenza hemagglutinin (HA) and neuraminidase (NA) pseudotyped viruses (Millet and Whittaker, 2014; Tse et al., 2014) .
Regulation of enveloped glycoprotein incorporation by C-terminal tail
The C-terminal tail or endodomain of class I viral fusion proteins plays important regulatory roles both for the fusion function but also for the incorporation of the protein into viral particles. It was shown that modifying the C-terminal tail of the Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) S protein was associated with enhanced envelope glycoprotein incorporation into retroviral pseudotyped particles (Moore et al., 2004) . The modifications included truncations within the C-terminal tail and addition of a portion of the cytoplasmic tail of the HIV-1 envelope glycoprotein. This could be a useful strategy to consider if the heterologous viral envelope glycoprotein fails to efficiently incorporate into pseudotyped particles.
